Interestingly, the loss of BNIP3 is associated with malignant progression in TNBC, and treating BNIP3-null cells with 2‐deoxyglucose (2DG) to inhibit glycolysis has been demonstrated to effectively suppress breast cancer growth in vitro [59]. Here, BNIP3 is linked to breast carcinoma.